Sign in

CIK 0001620463

  • Non-accelerated filer
  • Smaller reporting company

LeonaBio, Inc.

Sign in to watch
Ticker
LONA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
453368487
Phone
+1 425-620-8501
Business address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011
Former names
Athira Pharma, Inc., M3 Biotechnology, Inc.
Open-market buys, last 90 days
$9,919,161,281
in 1 filing
Open-market sales, last 90 days
$0
in 0 filings

Net +$9,919,161,281. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Portman David J. +$9.9B 10% owner 1 filing
Date Insider Transaction Shares Price Value Owned after
2021-02-03 FLUKE JOHN M JR Director Exercise or conversion +25,220 $1.19 $30K 140,101
2021-02-03 FLUKE JOHN M JR Director Exercise or conversion +3,783 $1.35 $5K 143,884
2021-02-03 FLUKE JOHN M JR Director Exercise or conversion · Stock Option (Right to Buy) −25,220 0
2021-02-03 FLUKE JOHN M JR Director Exercise or conversion · Stock Option (Right to Buy) −3,783 0
2021-01-25 PERCEPTIVE ADVISORS LLC Director Purchase +311,111 $22.50 $7.0M 3,425,916
2020-12-11 Romano Kelly A Director Grant or award · Stock Option (Right to Buy) +27,742 27,742
2020-09-22 EDELMAN JOSEPH Director Conversion +1,644,785 2,055,981
2020-09-22 EDELMAN JOSEPH Director Purchase +1,058,824 $17.00 $18.0M 3,114,805
2020-09-22 EDELMAN JOSEPH Director Conversion · Series B Preferred Stock −1,644,785 0
2020-09-22 FLUKE JOHN M JR Director Conversion +12,610 63,050
2020-09-22 FLUKE JOHN M JR Director Conversion +51,831 114,881
2020-09-22 FLUKE JOHN M JR Director Conversion +6,731 6,731
2020-09-22 FLUKE JOHN M JR Director Conversion · Series A Preferred Stock −12,610 0
2020-09-22 FLUKE JOHN M JR Director Conversion · Series A-1 Preferred Stock −51,831 0
2020-09-22 FLUKE JOHN M JR Director Conversion · Series B-1 Preferred Stock −6,731 0
2020-09-22 Litton Mark James Chief Operating Officer Conversion +13,126 63,566
2020-09-22 Litton Mark James Chief Operating Officer Conversion +6,563 6,563
2020-09-22 Litton Mark James Chief Operating Officer Conversion +6,563 6,563
2020-09-22 Litton Mark James Chief Operating Officer Conversion +6,563 6,563
2020-09-22 Litton Mark James Chief Operating Officer Conversion · Series B Preferred Stock −13,126 0

Page 17 of 18 · 349 trades